GHTF STED

US joins other GHTF countries in pilot for harmonised submissions

On 26 June 2003, the US became the last of the Global Harmonization Task Force (GHTF) member countries to initiate a voluntary pilot programme to test the use of the internationally harmonised format and content to demonstrate compliance of a device with the GHTF essential principles, described in the Summary Technical Documentation for Demonstrating Conformity to the Essential Principles of Safety and Performance of Medical Devices (the `draft STED document)1. The FDA is encouraging manufacturers who intend to submit premarket approval applications (PMAs) and premarket notifications [510(k)s] to discuss the use of the STED content and format for certain devices, with the appropriate CDRH division. Examples of devices that may be considered in the pilot are listed in Table 1 although other devices may be considered on a case-by-case basis. The listed devices have been recognised as being of mutual interest to GHTF members. A guidance document has been developed by the FDA in order to assist sponsors in participating in the programme (see page 317). This is the final version of the draft issued in July 20012.

The STED was developed by study group 1 of the GHTF and issued as a working document in December 2000. The format is intended to reduce the burden on manufacturers...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.